Patents by Inventor Arthur J. KUDLA

Arthur J. KUDLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC BINDING AGENTS TARGETING THE IGF-1R AND ERBB3 PATHWAYS AND USES THEREOF
    Publication number: 20170210809
    Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.
    Type: Application
    Filed: December 7, 2016
    Publication date: July 27, 2017
    Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Alexey Alexandrovich LUGOVSKOY, Jonathan B. FITZGERALD, Lihui XU, Neeraj KOHLI
  • MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONS
    Publication number: 20170082630
    Abstract: Improved assays incorporating single-cell based image analysis that enable quantitation of expression of individual cellular proteins and heterogeneity in terms of individual cellular protein molecule numbers per cell at the single cell level and mapped across sections of clinical tissue samples are disclosed.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Bart S. Hendriks, Elena Geretti, Arthur J. Kudla, Matthew David Onsum, Violette Paragas, Sharon Moulis
  • MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONS
    Publication number: 20150111217
    Abstract: Improved assays incorporating single-cell based image analyses that enable quantitation of expression of individual cellular proteins and heterogeneity in terms of individual cellular protein molecule numbers per cell at the single cell level and mapped across sections of clinical tissue samples are disclosed.
    Type: Application
    Filed: June 20, 2013
    Publication date: April 23, 2015
    Inventors: Bart S. Hendriks, Elena Geretti, Arthur J. Kudla, Matthew David Onsum, Violette Paragas, Sharon Moulis
  • Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
    Patent number: 8877687
    Abstract: Methods and kits for detecting antibodies (e.g., anti-drug antibodies) specific for abundant body fluid components are provided. Such methods and kits permit the detection of, for example, human serum albumin in human body fluids, such as blood, plasma and serum.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: November 4, 2014
    Assignee: Merrimack Pharmaceuticals
    Inventors: Sam Shenghua Song, Arthur J. Kudla, Mark David Moody
  • ASSAYS FOR ANTI-DRUG ANTIBODIES IN THE PRESENCE OF ABUNDANT ENDOGENOUS PROTEIN COUNTERPART OF THE DRUG
    Publication number: 20130203616
    Abstract: Methods and kits for detecting antibodies (e.g., anti-drug antibodies) specific for abundant body fluid components are provided. Such methods and kits permit the detection of, for example, human serum albumin in human body fluids, such as blood, plasma and serum.
    Type: Application
    Filed: April 26, 2011
    Publication date: August 8, 2013
    Applicant: MERRIMACK PHARMACEUTICALS
    Inventors: Sam Shenghua Song, Arthur J. Kudla, Mark David Moody
  • BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF
    Publication number: 20120244163
    Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 27, 2012
    Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI